“…High expression of proliferating cell nuclear antigen, type IV collagenase, and VEGF define the proliferating phase, while bFGF and urokinase are highly expressed in both the proliferating and involuting phases of IH, but not in vascular malformations [ 44 ]. In recent years, bioinformatics has enabled the discovery of molecular markers related to IH diagnosis and prognosis, including FOXF1, CTNNB1, IL6, CD34, IGF2, and MAPK11 [ 58 , 59 ]. Additionally, APLN, APLNR, TMEM132A were identified as potential anti-angiogenesis therapeutic targets for IH, and FYN, KIF20A, POLD1, RAD54L, TYMS were involved in distinguishing proliferative and regressive IH lesions [ 60 , 61 ].…”